Defining high HIV incidence subgroups of Australian homosexual men: Implications for conducting HIV prevention trials in low HIV prevalence settings

HIV Medicine

Volumn 11, Issue 10, 2010, Pages 635-641

  Poynten, I M ^a   Jin, F ^a   Prestage, G P ^a   Kaldor, J M ^a   Kippax, S ^b   Grulich, A E ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Biomedical prevention; Clinical trials; HIV; HIV incidence; Pre exposure prophylaxis; Rectal microbicides

Indexed keywords

ANTIRETROVIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; METHAMPHETAMINE; MICROBICIDE; PSYCHEDELIC AGENT;

ADULT; ARTICLE; AUSTRALIA; COHORT ANALYSIS; COMMUNITY MEDICINE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MALE HOMOSEXUAL; PATIENT PARTICIPATION; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR;

ADMINISTRATION, RECTAL; ADOLESCENT; ADULT; AGED; ANTI-INFECTIVE AGENTS, LOCAL; ATTITUDE TO HEALTH; AUSTRALIA; CIRCUMCISION, MALE; CLINICAL TRIALS AS TOPIC; COHORT STUDIES; FACTOR ANALYSIS, STATISTICAL; HIV INFECTIONS; HOMOSEXUALITY, MALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PATIENT SELECTION; RISK FACTORS; SEXUAL BEHAVIOR; SUBSTANCE-RELATED DISORDERS; VACCINATION; YOUNG ADULT;

EID: 77958536331     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2010.00833.x     Document Type: Article

References (42)

1. Padian N, Buvś A, Balkus J, Serwadda D, Cates W Jr. Biomedical interventions to prevent HIV infection: evidence, challenges, and way forward. Lancet 2008; 372: 585-599.
2. HIV Prevention Trials Network. Ongoing Studies and Studies in Development. Available at (accessed 27 May 2009).
3. Alliance for Microbicide Development. HIV/STI Prevention Research and Development: May 2009 Pipeline Update of Microbicide and PrEP Candidates. Available at (accessed 27 May 2009).
4. Seage G III, Holte S, Metzger D et al. Are US populations appropriate for trials of human immunodeficiency virus vaccine? Am J Epidemiol 2001; 153: 619-627.
5. Van De Wijgert J, Jones H. Challenges in microbicide trial design and implementation. Studies Fam Plan 2006; 37: 123-128.
6. Feldblum P, Adeiga A, Bakare R et al. SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PLoS ONE 2008; 3: e1474.
7. Hira S, Feldblum P, Kamanga J, Mukelabai G, Weir S, Thomas J. Condom and nonoxynol-9 use and the incidence of HIV infection in serodiscordant couples in Zambia. Int J STD AIDS 1997; 8: 243-250.
8. Kreiss J, Ngugi E, Holmes K et al. Efficacy of nonoxynol 9 contraceptive sponge use in preventing heterosexual acquisition of HIV in Nairobi prostitutes. J Am Med Ass 1992; 268: 521-523.
9. Roddy R, Zekeng L, Ryan K, Tamoufe U, Weir S, Wong E. A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases. New Engl J Med 1998; 339: 504-510.
10. Van Damme L, Ramjee G, Alary M et al. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet 2002; 360: 971-977.
11. Weir S, Roddy R, Zekeng L, Feldblum P. Nonoxynol-9 use, genital ulcers, and HIV infection in a cohort of sex workers. Genitourinary Med 1995; 71: 78-81.
12. Zekeng L, Feldblum P, Oliver R, Kaptue L. Barrier contraceptive use and HIV infection among high-risk women in Cameroon. AIDS 1993; 7: 725-731.
13. Skoler-Karpoff S, Ramjee G, Ahmed K et al. Efficacy of carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372: 1977-1987.
14. Van Damme L, Govinden R, Mirembe F et al. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. New Engl J Med 2008; 359: 463-472.
15. Peterson L, Nanda K, Opoku B et al. SAVVY (C31G) gel for prevention of HIV infection in women: a phase 3, double-blind, randomized, placebo-controlled trial in Ghana. PLoS ONE 2007; 2: e1312.
16. Peterson L, Taylor D, Roddy R et al. Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial. PLoS Clinical Trials 2007; 2: e27.
17. HIV Vaccine Trials Network. Current vaccine trials. Available at (accessed 27 May 2009).
18. The rgp120 HIV Vaccine Study Group. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005; 191: 654-665.
19. Rerks-Ngarm S, Brown A, Khamboonruang C, Thongcharoen P, Kunasol P. HIV/AIDS preventive vaccine 'prime-boost' phase III trial: foundations and initial lessons learned from Thailand. AIDS 2006; 20: 1471-1479.
20. Duerr A, Wasserheit J, Corey L. HIV Vaccines: new frontiers in vaccine development. Clin Infect Dis 2006; 43: 500-511.
21. Jin F, Prestage G, McDonald A et al. Trend in HIV incidence in a cohort of homosexual men in Sydney: data from the health in men study. Sexual Health 2008; 5: 109-112.
22. Grulich A, Kaldor J. Trends in HIV incidence in homosexual men in developed countries. Sexual Health 2008; 5: 113-118.
23. Centers for Disease Control and Prevention. Trends in HIV/AIDS diagnoses among men who have sex with men - 33 states, 2001-2006. J Am Med Assoc 2008; 300: 497-499.
24. Merson M, O'Mally J, Serwadda D, Apisuk C. The history and challenge of HIV prevention. Lancet 2008; 372: 475-488.
25. Kelleher A, Puls R, Bebbington M et al. A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1. AIDS 2006; 20: 294-297.
26. Jin F, Prestage G, Mao L et al. Transmission of herpes simplex virus types 1 and 2 in a prospective cohort of HIV-negative gay men: the health in men study. J Infect Dis 2006; 194: 561-570.
27. Jin F, Crawford J, Prestage G et al. Unprotected anal intercourse, risk reduction behaviours, and subsequent HIV infection in a cohort of homosexual men. AIDS 2009; 23: 243-252.
28. Poynten I, Jin F, Mao L et al. Non-occupational post-exposure prophylaxis, subsequent risk behaviour and HIV incidence in a cohort of Australian homosexual men. AIDS 2009; 23: 1119-1126.
29. Templeton D, Jin F, Prestage G et al. Circumcision and risk of sexually transmissible infections in a community-based cohort of HIV-negative homosexual men in Sydney, Australia. J Infect Dis 2009; 200: 1813-1819.
30. Jin F, Prestage G, Imrie J et al. Anal sexually transmissible infections and risk of HIV infection in homosexual men. J Infect Dis 2010; 53: 144-149.
31. Prestage GP, Jin F, Kippax S, Zablotska I, Imrie J, Grulich AE. The use of illicit drugs and erectile dysfunction medications and subsequent HIV infection among gay men in Sydney, Australia. Journal of Sexual Medicine 2009; 6(8): 2311-2320.
32. Bartholow B, Goli V, Ackers M et al. Demographic and behavioral contextual risk groups among men who have sex with men participating in a phase 3 HIV vaccine efficacy trial. J Acquired Immune Defic Syndr 2006; 43: 594-602.
33. Koblin B, Husnik M, Colfax G et al. Risk factors for HIV infection among men who have sex with men. AIDS 2006; 20: 731-739.
34. Harro C, Judson F, Gorse G et al. Recruitment and baseline epidemiologic profile of participants in the first Phase 3 HIV vaccine efficacy trial. J Acquired Immune Defic Syndr 2004; 37: 1385-1392.
35. Harrison L, Do Lago R, Friedman R et al. Incident HIV infection in a high-risk, homosexual, male cohort in Rio de Janeiro, Brazil. J Acquired Immune Defic Syndr 1999; 21: 408-412.
36. Van De Ven P, Bartholow B, Rawstorne P et al. Scaling HIV vaccine attitudes among gay men in Sydney, Australia. AIDS Res Hum Retroviruses 2002; 18: 1333-1337.
37. Van de Ven P, Mao L, Crawford J et al. Willingness to participate in HIV vaccine trials among HIV-negative gay men in Sydney, Australia. Int J STD AIDS 2005; 16: 314-317.
38. Buchbinder S, Douglas JJ, McKirnan D, Judson F, Katz M, MacQueen K. Feasibility of human immunodeficiency virus vaccine trials in homosexual men in the United States: risk behavior, seroincidence, and willingness to participate. J Infect Dis 1996; 174: 954-961.
39. Koblin B, Heagerty P, Sheon A et al. Readiness of high-risk populations in the HIV network for prevention trials to participate in HIV vaccine efficacy trials in the United States. AIDS 1998; 12: 785-793.
40. Colfax G, Buchbinder S, Vamshidar G et al. Motivations for participating in an HIV vaccine efficacy trial. J Acquired Immune Defic Syndr 2005; 39: 359-364.
41. Djomand G, Metch B, Zorrilla C et al. The HVTN Protocol 903 vaccine preparedness study. Lessons learned in preparation for HIV vaccine efficacy trials. J Acquired Immune Defic Syndr 2008; 48: 82-89.
42. Buchbinder S, Mehrotra D, Duerr A et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008; 372: 1881-1893.